ESTRO 35 2016 _____________________________________________________________________________________________________ cosmetic outcome was good/excellent in 94% of patients. At one year skin toxicity was G1 in 13% of patients, 1 patient G2, 1 patient G3; cosmetic outcome was good/excellent in 93% of patients.After an early evaluation of clinical outcomes we have found 12 cases of progression disease, only one patient had an In-Breast-Recurrence.
Results:
Luminal-A patients represented the 61.5% of the whole series (151 WBI versus 169 APBI). 5-year event rate according to allocated group showed no statistical difference in terms of IBTR (p=0.53). One case (0.9%) versus two cases (1.7%) were observed in the WBI and APBI arms, respectively. Survival events occurrences and IBTR curve are summarized in the Figures.
Conclusion:
We observed a very low 5-year rate of IBTR for Luminal-A patients treated with APBI. Although these results should be confirmed at a longer follow up time, this approach should be considered for this subset of early BC patients.
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The impact of chemotherapy on toxicity in the era of hypofractionated radiotherapy M.C. De Santis 
Material and Methods:
From April 2009 to December 2014, 540 patients received radiotherapy after breast conservative surgery (BCS). The dose was 42.4 Gy in 16 daily fractions, 2.65 Gy per fraction. The boost to the tumor bed was administered only in grade 3 patients and in patients with close or positive margins. Acute and late toxicity were prospectively assessed during and after radiotherapy according to RTOG scale. The impact of patients clinical characteristics and dose inhomogeneities on the occurrence of an higher level of toxicity has been also evaluated by univariate and multivariate analysis.
Results:
One hundred and nineteen patients received chemotherapy. Sixty-one patients (11.3%) underwent trastuzumab therapy and four hundred and forty-one (81.6%) hormonotherapy. The mean age was 74 (range 46-91 yrs). Forty seven (8.7%) and two hundred fifty eight (47.5%) patients were affected by diabetes mellitus and hypertension, respectively. G1 and G2/G3 acute skin toxicity were 53.7% and 28.5% in patients received chemotherapy and 63.2% and 18.5% in patients who did not receive it, respectively. No significant difference (p=0.092) was find between the two groups of treatment. The boost administration (p< 0.01), the breast volume (p 0.04), dose inhomogeneities (p<0.01) and boost volume (0.04) were found to be statistically significant as concerns the occurrence of acute skin reaction at the univariate analysis; the boost administration (p< 0.01), and hormonotherapy (p 0.01) at multivariate analysis. Other clinical factors such as diabetes or hypertension were not correlated with the development of acute skin reaction. G1 and G2/G3 late fibrosis were 15.3% and 8.1% in patients received chemotherapy and 12.3% and 3.1% in patients who did not receive it, with a significant difference (p=0.045) between the two groups. Diabetes (p 0.04) and boost administration (p <0.01) were also found to be statistically significant on the occurrence of late fibrosis, but a multivariate analysis adjusted also for clinical tumour characteristics did not show any factors correlated to late fibrosis .
Conclusion:
The results of our study, according to the large randomized trials, confirmed that hypofractionated whole breast irradiation is safe, even in patients treated with chemotherapy. Chemotherapy didn't impact on acute toxicity but only on late toxicity; however the percentage of G2-G3 fibrosis is low (8.1 vs 3.1%). Our study confirmed an increase of acute and late toxicity in patients who received additional boost. The effect of radiotherapy (RT) on the outcome of autologous reconstruction after mastectomy for breast cancer is unclear. Advances in technique such as the deep inferior epigastric artery perforator (DIEP) flap and IMRT may affect the complication rate. We seek to retrospectively evaluate the outcomes after flap reconstruction at our institution with a focus on radiotherapy variables.
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Material and Methods:
Patients receiving flap reconstruction after mastectomy at our institution from 2003-2014 were identified in a chart review. Analysis was limited to patients with a coded cancer status and who returned for at least one follow up visit. The outcome variables analyzed were flap loss or any complication (loss, ischemia, hematoma, infection). Descriptive data analyzed included age, tumor stage, flap type, chemotherapy, and radiation. RT specific variables included radiation at an academic medical center vs independent radiotherapy facility, 3D-CRT vs IMRT, and whether radiation was directed to the internal mammary (IM) region. Analyses was on a per-flap basis rather than per patient. Statistics were done in SPSS using logistic regression. Two prognostic models were generated. The first included all patients and analyzed age, stage, flap type, chemotherapy, and radiation therapy. The second model included only those receiving radiation therapy and included significant factors from the first model and the RT variables discussed above. I, 88 (20.1%) were for stage II, 52 (11.9%) were for stage III, and 3 (0.7%) were for stage IV disease. 146 (33.3%) received RT and 187 (42.7%) received neoadjuvant chemotherapy. Of those receiving RT, 42 (28.7%) received 3D-CRT, 38 (26.0%) received IMRT, and 66 (44.5%) had unknown RT technique. 28 (6.9%) flaps failed and 64 (15.9%) flaps had a complication. The first model, which included all patients, identified increasing cancer stage (p=0.03) as the most important variable for flap loss with a hazard ratio of 3.4 for DCIS/LCIS, 2.1 for stage I, 7.3 for stage II, and 1.8 for stage III compared to benign pathology. Age was the only variable associated with increased overall complications. In the second model, location of RT, RT technique, and IM directed radiation were not significant predictors of flap loss or complications.
Results
